| P2093 | author name string | Neal D Shore | |
| P2860 | cites work | Therapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate Cancer | Q26750620 |
| | Therapy escape mechanisms in the malignant prostate | Q26795611 |
| | ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer | Q26796568 |
| | AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer | Q27853062 |
| | New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) | Q28131668 |
| | Increased survival with enzalutamide in prostate cancer after chemotherapy | Q29617511 |
| | Abiraterone and increased survival in metastatic prostate cancer | Q29617512 |
| | Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group | Q33566395 |
| | Enzalutamide in metastatic prostate cancer before chemotherapy | Q34422206 |
| | Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial | Q34426881 |
| | Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies | Q34483362 |
| | Irrefutable evidence for the use of docetaxel in newly diagnosed metastatic prostate cancer: results from the STAMPEDE and CHAARTED trials | Q35875775 |
| | Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance | Q36470627 |
| | Castration-resistant prostate cancer: AUA guideline amendment | Q38274746 |
| | Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort | Q38392787 |
| | Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Chemotherapy-naïve and CYP17 Inhibitor-naïve Patients: Follow-up from the ARADES and ARAFOR Trials | Q38655024 |
| | Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Castration-resistant, CYP17 Inhibitor-naïve Prostate Cancer: Results from Extended Follow-up of the ARADES Trial | Q38655027 |
| | Bone Scan Index and Progression-free Survival Data for Progressive Metastatic Castration-resistant Prostate Cancer Patients Who Received ODM-201 in the ARADES Multicentre Study | Q38672112 |
| | EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent | Q38939206 |
| | Cancer Statistics, 2017. | Q39038674 |
| | The 2015 CUA-CUOG Guidelines for the management of castration-resistant prostate cancer (CRPC). | Q42721450 |
| | Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 | Q45957143 |
| | Pharmacokinetics, Antitumor Activity, and Safety of ODM-201 in Patients with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: An Open-label Phase 1 Study. | Q53664046 |
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | prostate cancer | Q181257 |
| | darolutamide | Q25091391 |
| P304 | page(s) | 945-952 | |
| P577 | publication date | 2017-05-11 | |
| P1433 | published in | Expert Opinion on Pharmacotherapy | Q5421212 |
| P1476 | title | Darolutamide (ODM-201) for the treatment of prostate cancer | |
| P478 | volume | 18 | |